logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

Feb 10, 2021•almost 5 years ago

Amount Raised

$130 Million

Round Type

series b

San Francisco

Description

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors. The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

Company Information

Company

Day One Biopharmaceuticals

Location

San Francisco, California, United States

About

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The company believes in putting kids first and is developing targeted therapies that deliver to their needs. Day One was founded to address the dire lack of therapeutic development in pediatric cancer and aims to re-envision cancer drug development starting from Day One.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech